Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 1, 51-61, January 2007; doi:10.1634/theoncologist.12-1-51
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sonpavde, G.
Right arrow Articles by Roth, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sonpavde, G.
Right arrow Articles by Roth, B. J.

Genitourinary Cancer

Management of Recurrent Testicular Germ Cell Tumors

Guru Sonpavdea, Thomas E. Hutsona, Bruce J. Rothb

a U.S. Oncology Research, Houston, Texas, USA; b Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA

Key Words. Germ cell tumors • Salvage

Correspondence: Guru Sonpavde, M.D., 501 Medical Center Blvd., Webster, Texas 77598, USA. Telephone: 281-332-7505; Fax: 281-332-8429; e-mail: guru.sonpavde{at}usoncology.com

Although front-line chemotherapy cures most men with testicular germ cell tumors, salvage therapy is still important in a small but significant minority. Second-line conventional-dose or high-dose chemotherapy with stem cell rescue may cure 25%–50% of patients. New chemotherapeutic agents, including the taxanes gemcitabine and oxaliplatin, have added to the therapeutic armamentarium. Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. Inoue, F. Koga, S. Kawakami, N. Numao, M. Sakura, T. Kobayashi, and K. Kihara
False Tumor Marker Surge Evoked by Peripheral Blood Stem Cell Transplantation
Oncologist, May 1, 2008; 13(5): 526 - 529.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement